Immune Dysfunction in Multiple Sclerosis: Modern Considerations in Treatment and Management

Target Audience

The target audience for the activity titled Immune Dysfunction in Multiple Sclerosis: Modern Considerations in Treatment and Management is neurologists, nursing professionals, PAs and other healthcare professionals involved in the management of patients with MS.

Learning Objectives

• Describe regulation and dysregulation of the adaptive and the innate immune systems during development and progression of MS
• Review the mechanisms of action of current and emerging immunotherapies for MS and their relevance to treatment decisions
• Discuss immune-related toxicities of current and emerging immunotherapies used for MS
• Utilize strategies to assess and manage immune-related toxicities
• Evaluate relative risks and benefits of immunotherapeutic options
• Employ patient-specific considerations when making treatment-sequencing decisions

Provided by The Consortium of Multiple Sclerosis Centers, International Organization of Multiple Sclerosis Nurses, and Catamount Medical Education.

This activity is supported by independent educational grants from Biogen, EMD Serono, Novartis Pharmaceuticals Corporation, and Sanofi Genzyme.

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Consortium of Multiple Sclerosis Centers (CMSC), International Organization of Multiple Sclerosis Nurses (IOMSN), and Catamount Medical Education. CMSC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit Designations

Physician Continuing Medical Education
The CMSC designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit Designation
​The CMSC designates this activity for a maximum of 1.0 contact hours of continuing nursing education.

Pharmacist Credit Designations
This knowledge-based activity (JA4008165-9999-20-066-L01-P) qualifies for 1.0 contact hour (0.1 CEUs) of continuing pharmacy education credit.

Disclosure of Conflicts of Interest

It is the policy of the Consortium of Multiple Sclerosis Centers (CMSC) to ensure balance, independence, objectivity, and scientific rigor in all educational activities. All faculty, planning committee members, content reviewers, and staff participating in this activity have disclosed any relevant financial relationships they or their significant other have had within the previous 12 months with manufacturers of any commercial products/devices and/or providers of commercial services included in this educational activity. The intent of this disclosure is not to prevent a person with a relevant financial relationship from participating in the activity, but rather to provide participants with information on which they can base their own judgments. All presentations were reviewed by an independent clinician with no relevant financial relationships for the purpose of resolution of any identified conflict of interest and a determination of evidence-base and fair balance.

Faculty Disclosures:
Fred D Lublin, MD
Saunders Family Professor of Neurology
Director, The Corinne Goldsmith Dickinson Center for Multiple Sclerosis
Icahn School of Medicine at Mount Sinai

Dr. Lublin has disclosed the following relationships:
Sources of Funding for Research: Novartis Pharmaceuticals Corp; Teva Neuroscience; Actelion; Transparency Life Sciences; NMSS, Sanofi
Consulting Agreements/Advisory Boards/DSMB: Bayer HealthCare Biogen; EMD Serono; Novartis; Teva; Actelion; Sanofi/Genzyme; Acorda; Roche/Genentech; MedImmune; Receptos/Celgene; Forward Pharma; TG Therapeutics; Abbvie; Regeneron; Medday; Atara Biotherapeutics; Polpharma; Mapi Pharma; Innate Immunotherapeutics; Apitope; Orion Biotechnology; Brainstorm Cell Therapeutics

Accreditor and Planning Committee Disclosures:
June Halper, MSN, APN-C, MSCN, FAAN, has declared that she has no relevant financial relationships to disclose.

All other planners, reviewers, staff, or other members of the Continuing Professional Education Committee at the Consortium of Multiple Sclerosis Centers who control content have disclosed no relevant financial relationships.

Planners, reviewers, staff, or other members of International Organization of Multiple Sclerosis Nurses who control content have disclosed no relevant financial relationships.

Laurie Scudder, DNP, NP, has served as Nurse Planner for this activity. She has declared that she has no relevant financial relationships to disclose.

Publishing Staff Disclosures:
The planners, reviewers, editors, staff, CME committee, or other members at Catamount Medical Education who control content have disclosed no relevant financial relationships.